Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty

Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty

The use of abciximab after full-dose failed thrombolytics within 15 hours of acute myocardial infarction significantly increases the risk of major bleeding complications.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The American journal of cardiology 1999-06, Vol.83 (11), p.1569-1570
Hauptverfasser: Sundlof, Deborah W, Rerkpattanapitat, Pairoj, Wongpraparut, Nattawut, Pathi, Padmavathi, Kotler, Morris N, Jacobs, Larry E, Ledley, Gary S, Yazdanfar, Shahriar
Format: Artikel
Sprache:eng
Schlagworte:
Abciximab
Aged
Angioplasty
Angioplasty, Balloon, Coronary
Antibodies, Monoclonal - adverse effects
Cardiology
Female
Hemorrhage - epidemiology
Hemorrhage - etiology
Humans
Immunoglobulin Fab Fragments - adverse effects
Incidence
Male
Medical procedures
Medical research
Middle Aged
Myocardial Infarction - drug therapy
Myocardial Infarction - therapy
Platelet Aggregation Inhibitors - adverse effects
Retrospective Studies
Thrombolytic Therapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The use of abciximab after full-dose failed thrombolytics within 15 hours of acute myocardial infarction significantly increases the risk of major bleeding complications.
ISSN:0002-9149
1879-1913
DOI:10.1016/S0002-9149(99)00151-4